Clinical trials

  • AMLITELIMAB for Atopic dermatitis
  • PEMAFIBRATE for Nonalcoholic steatohepatitis (NASH) with liver fibrosis
  • TISAGENLECLEUCEL for B-cell acute lymphoblastic leukemia|High-risk B-cell acute lymphoblastic leukemia
  • CYCLOPHOSPHAMIDE for Lymphoblastic lymphoma
  • DISODIUM FOLINATE for Locally advanced resectable colon cancer (T3-4 and/or node-positive, M0)
  • 1-{6-[(4M)-4-(5-CHLORO-6-METHYL-1H -INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H -INDAZOL-5-YL)-1H -PYRAZOL-1-YL]-2-AZASPIRO[3.3]HEPTAN-2-YL}PROP-2-EN-1-ONE for KRAS G12C-mutant advanced solid tumors | Non-small cell lung cancer | Colorectal cancer
  • RASBURICASE for Sepsis
  • (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE for ER-positive breast cancer
  • Bispecific antibody targeting CEACAM5 and CD3 for Colorectal cancer (locally advanced or metastatic)
  • RILVEGOSTOMIG for Advanced HER2-expressing biliary tract cancer
  • CEACAM5 x CD3 antibody for Locally advanced or metastatic colorectal cancer (low tumor volume)
  • SEMAGLUTIDE for Obesity